Nonacog beta pegol in previously treated children with hemophilia B: results from an international open-label phase 3 trial
Nonacog beta pegol in previously treated children with hemophilia B: results from an international open-label phase 3 trial
Essentials
Nonacog beta pegol is a recombinant glycoPEGylated factor IX with an extended half‐life.
This phase 3 trial investigated its safety/efficacy in previously treated hemophilia B boys ≤ 12 years.
A 40 IU kg−1 dose provided effective once‐weekly prophylaxis and hemostasis when used to treat bleeds.
Nonacog beta pegol was well tolerated in previously treated boys ≤ 12 years with hemophilia B.
1521-1529
Carcao, M.
c2f20802-3c85-42d8-83a1-0cb9da2876a7
Zak, M.
217ec69e-e634-4f7d-994e-287e48f7a3ae
Abdul Karim, F.
7a385b5a-196e-4677-9f44-a398969cfdd9
Hanabusa, H.
9b921f9c-78f4-48e5-9128-5d9ef3571e43
Kearney, S.
8ea908f6-178a-4234-896f-6d06dd4a0842
Lu, M.-y.
db9b219e-d19f-4246-9860-04b103a87e4c
Persson, P.
c6d3dd61-8524-453d-849d-ffa7bbafc403
Rangarajan, S.
9a5e4c7e-55ba-4a3a-b5f6-f1e269d927c3
Santagostino, E.
43deb3c2-fa5c-4d17-a8e5-960a9119f636
1 August 2016
Carcao, M.
c2f20802-3c85-42d8-83a1-0cb9da2876a7
Zak, M.
217ec69e-e634-4f7d-994e-287e48f7a3ae
Abdul Karim, F.
7a385b5a-196e-4677-9f44-a398969cfdd9
Hanabusa, H.
9b921f9c-78f4-48e5-9128-5d9ef3571e43
Kearney, S.
8ea908f6-178a-4234-896f-6d06dd4a0842
Lu, M.-y.
db9b219e-d19f-4246-9860-04b103a87e4c
Persson, P.
c6d3dd61-8524-453d-849d-ffa7bbafc403
Rangarajan, S.
9a5e4c7e-55ba-4a3a-b5f6-f1e269d927c3
Santagostino, E.
43deb3c2-fa5c-4d17-a8e5-960a9119f636
Carcao, M., Zak, M., Abdul Karim, F., Hanabusa, H., Kearney, S., Lu, M.-y., Persson, P., Rangarajan, S. and Santagostino, E.
(2016)
Nonacog beta pegol in previously treated children with hemophilia B: results from an international open-label phase 3 trial.
Journal of Thrombosis and Haemostasis, 14 (8), .
(doi:10.1111/jth.13360).
Abstract
Essentials
Nonacog beta pegol is a recombinant glycoPEGylated factor IX with an extended half‐life.
This phase 3 trial investigated its safety/efficacy in previously treated hemophilia B boys ≤ 12 years.
A 40 IU kg−1 dose provided effective once‐weekly prophylaxis and hemostasis when used to treat bleeds.
Nonacog beta pegol was well tolerated in previously treated boys ≤ 12 years with hemophilia B.
This record has no associated files available for download.
More information
Accepted/In Press date: 12 April 2016
e-pub ahead of print date: 13 May 2016
Published date: 1 August 2016
Identifiers
Local EPrints ID: 442893
URI: http://eprints.soton.ac.uk/id/eprint/442893
ISSN: 1538-7933
PURE UUID: 54921e88-946a-4557-be18-482c006643ce
Catalogue record
Date deposited: 30 Jul 2020 16:31
Last modified: 17 Mar 2024 04:02
Export record
Altmetrics
Contributors
Author:
M. Carcao
Author:
M. Zak
Author:
F. Abdul Karim
Author:
H. Hanabusa
Author:
S. Kearney
Author:
M.-y. Lu
Author:
P. Persson
Author:
E. Santagostino
Download statistics
Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.
View more statistics
